Capricor Therapeutics (CAPR) Free Cash Flow (2010 - 2026)
Capricor Therapeutics (CAPR) posted quarterly Free Cash Flow of -$34.4 million for Q1 2026, down 369.02% year-over-year from $12.8 million in Q1 2025, and down 36.24% quarter-over-quarter from -$25.2 million in Q4 2025.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Free Cash Flow (2010 - 2026) Analysis & Trends
Capricor Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$34.4 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 369.02% year-over-year to -$34.4 million; the TTM figure through Mar 2026 stood at -$99.8 million (down 114.01% YoY), while the FY2025 annual figure was -$72.7 million, down 76.65% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$34.4 million, down from -$25.2 million in the prior quarter.
- The five-year high for Free Cash Flow was $23.5 million in Q1 2022, with the low at -$34.4 million in Q1 2026.
- The 5-year median for Free Cash Flow is -$9.6 million (2023), against an average of -$10.1 million.
- The sharpest annual moves came in 2022 and 2026: Free Cash Flow surged 797.47% in 2022, then plunged 369.02% in 2026.
- Capricor Therapeutics' Free Cash Flow stood at -$7.6 million in 2022, then sank by 59.99% to -$12.2 million in 2023, then fell by 25.78% to -$15.3 million in 2024, then sank by 65.07% to -$25.2 million in 2025, then tumbled by 36.24% to -$34.4 million in 2026.
- Business Quant data shows CAPR's Free Cash Flow at -$34.4 million in Q1 2026, -$25.2 million in Q4 2025, and -$19.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | -35.55 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -35.55 Mn |
| Mar 31, 2026 | -34.38 Mn |
| Dec 31, 2025 | -25.23 Mn |
| Sep 30, 2025 | -19.74 Mn |
| Jun 30, 2025 | -20.41 Mn |
| Mar 31, 2025 | -7.33 Mn |
| Dec 31, 2024 | -15.29 Mn |
| Sep 30, 2024 | -11.65 Mn |
| Jun 30, 2024 | -12.35 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Dec 31, 2023 | -12.15 Mn |
| Sep 30, 2023 | -9.06 Mn |
| Jun 30, 2023 | -9.55 Mn |
| Mar 31, 2023 | 3.86 Mn |
| Dec 31, 2022 | -7.60 Mn |
| Sep 30, 2022 | -6.24 Mn |
| Jun 30, 2022 | -6.72 Mn |
| Mar 31, 2022 | 23.48 Mn |
| Dec 31, 2021 | -6.00 Mn |
| Sep 30, 2021 | -3.81 Mn |